Alto NeuroscienceANRO
Recorded

Alto Neuroscience Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration29 minParticipants1

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Speaker

Good morning, everybody. Happy to be hosting this panel with Amit Etkin, Founder and CEO of Alto Neuroscience. I'm going to kick it over to Amit to maybe just make some brief opening remarks, set the stage on the key programs and where they're at going into 2027. You also just had your earnings update yesterday, and maybe you can just give us a little tidbit there, and we'll do Q&A.

Amit EtkinFounder and CEO

Thank you. Great. Good morning.

Amit EtkinFounder and CEO

Thank you for having us here. Alto Neuroscience, just to bring everybody up to speed, is a late-stage psychiatry drug developer, taking a variety of approaches across disorders like major depression, treatment-resistant depression, bipolar depression, as well we've done work in other areas like schizophrenia, to develop novel drugs, often guided by ways to select patients for better response through biomarkers, things like EEG and cognitive measures. Our lead asset is ALTO-207, which is a fixed-dose combination of pramipexole, which is a D3-preferring direct full dopamine agonist, and ondansetron. That combination allows faster and higher dosing of pramipexole in that fixed-dose combination. Pramipexole itself has a boatload of efficacy history behind it, but the issue being nausea and vomiting that's induced by any dopamine agonist, and that's where the ondansetron comes in.

Amit EtkinFounder and CEO

It's a program based on a lot of years of research, and we'll talk about that in terms of clinical efficacy. We also have ALTO-300, which is a drug, agomelatine, approved in Europe, being developed here as an adjunctive treatment in depression. The comparison set being antipsychotic medications, and the drug itself is a very well-tolerated, different mechanism of action, and we use an EEG biomarker to additionally enrich the population. Then ALTO-100, which is a pro-neuroplasticity first-in-class compound for bipolar depression patients characterized by impairments in neuroplasticity through a test of learning and memory. We put out our earnings, which essentially said last night, that everything is on track.

Amit EtkinFounder and CEO

The guidances are first half next year for ALTO-300 phase II-B readout, mid-next year for ALTO-100 phase II-B readout, and then second half next year for ALTO-207 phase II-B readout, with $320 million in cash covering us through 2030, and execution not only on those programs, but the full phase III program for ALTO-207 in treatment-resistant depression patients. The expectation that we've been discussing is that all of the data that we've been collecting, phase I data that we'll talk about, blinded phase II data, goes to the FDA for a Q4 feedback on the question of essentially, can we get started with a phase III program, which we're guiding to a start in early 2027, assuming alignment with the FDA. That's really the event this quarter.

Amit EtkinFounder and CEO

But gearing up for that start, everything is tracking well in terms of guidance. Then likewise, we've been anticipating a start for a second phase III for indication expansion in ALTO-207 second half next year, so that we have, through that, the broadest depression label, both adjunctive and monotherapy use in treatment-resistant depression patients, which is very, very exciting.

Speaker

That's great. On the FDA dialogue around forging ahead with a phase III, pramipexole and ondansetron are well-known drugs, so what question are you trying to get the FDA comfortable with to give you the green light?

Amit EtkinFounder and CEO

The main question is actually just the timing of start. So what we're aiming to do here is start the phase III before the phase IIb reads out. The primary motivation for that is, of course, to get the drug through NDA and approval as soon as possible. The information that we have on both efficacy and safety, not just from what we've collected, but what we know as a whole, is quite massive. So really, it's a benefit-risk calculation here around the timing. So the benefit side, the argument is based on 25 years of research where different groups have shown consistent outsized efficacy signals, most notably the PAX-D study that came out last year in Lancet Psychiatry, which showed an almost Cohen's d of 0.9 effect size in very resistant TRD patients, and that's three times the average successful antidepressant effect size.

Amit EtkinFounder and CEO

And that's been consistent across every study published over the past 25 years. On the tolerability side, there's data that we have collected, part of these phase Is, for example, and that the originator of this combination collected, Chase Therapeutics, showing that adding ondansetron improves tolerability of pramipexole and allows you to dose faster and higher in a well-tolerated way, which is critical for harnessing that efficacy. Then we know certainly historically in terms of exposure levels and chronic safety of these two drugs, and doing this within a 505(b)(two) path, that we can harness a lot of that safety information.

Amit EtkinFounder and CEO

The argument here is a risk-benefit argument to FDA to start that phase III before the phase IIb reads out, because if you then take those two pieces and you have enough visibility on safety and you have historical information about tolerability, then really there's not a lot of advantage to waiting for the phase IIb. This is for the FDA to decide. We've put a good argument in front of them. We've also proposed a specific design following the current phase IIb, very, very similar. It's an eight-week total treatment duration, the same two-week titration schedule.

Amit EtkinFounder and CEO

While we are studying a dose of 3.2 milligrams of pramipexole together with 15 milligrams of ondansetron in the phase IIb, that would now be the highest of two doses that we would power for registration in the phase III, the lower dose being half of that at 1.6 milligrams. You have a nice step in terms of understanding dose response on the pramipexole side. All of those things we'll get feedback on, and we'll give them as well blinded data in terms of tolerability for the phase IIb that's ongoing.

Speaker

Yeah. Okay, great. We'll get that update relatively soon?

Amit EtkinFounder and CEO

That'll be either late this quarter, or early next year, just depending on their feedback. We're obviously at the whim of their timing.

Amit EtkinFounder and CEO

Right. The feedback we will provide is this critical question of, can we proceed with a phase III, currently guided for early 2027, plus information on essentially what they saw.

Amit EtkinFounder and CEO

The phase I data deal with PK, the goal of the PK being to show that we have a modified release formulation where we have nicely PK matched these two components, pramipexole and ondansetron, which have two different half-lives, and that PK matching them certainly could contribute well to the tolerability profile, because having pramipexole stick around longer while ondansetron falls off obviously can create side effects that are not being countered. We have a dose ranging on the ondansetron side. The question FDA wanted us to answer was, can you get away with less ondansetron? We think 15 milligrams is still well supported by the data.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day